JP Patent

JP6041823B2 — トファシチニブの経口持続放出剤形

Assigned to ファイザー・インク · Expires 2016-12-14 · 9y expired

What this patent protects

Patent listed against Xeljanz.

Drugs covered by this patent

Xeljanz (Tofacitinib Citrate) · Pfizer

Patent Metadata

Patent number: JP6041823B2
Jurisdiction: JP
Classification: —
Expires: 2016-12-14
Drug substance claim: No
Drug product claim: No
Assignee: ファイザー・インク
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.